---
$id: https://graph.org.ai/products/commodity/51181526
$type: Product
source: UNSPSC
code: "51181526"
title: "Epalrestat"
class: "51181500"
classTitle: "Antidiabetic agents and hyperglycemic agents"
family: "51180000"
familyTitle: "Hormones and hormone antagonists"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Epalrestat

**UNSPSC Code**: 51181526
**Class**: [Antidiabetic agents and hyperglycemic agents](Antidiabetic agents and hyperglycemic agents.mdx)
**Family**: [Hormones and hormone antagonists](../Hormones and hormone antagonists.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an aldose reductase inhibitor with the molecular formula C15H13NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 424DV0807X, chemically known as 5-((z,e)-beta-methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid but generally known as epalrestat, which bears US NIH Compound Identifier 1549120. European Medicines Agency schedules Epalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06557MIG. The term EPALRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). EPALRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epalrestat under HS 29341000 and SITC 51579. As of Q4 2014, EPALRESTAT remains the US FDA Preferred Term for this commodity. Epalrestat bears US NLM identifiers UMLS ID C0095278 and NCI Concept Code C72762. SMILES: S1/C(=C\C(=C\C2CCCCC2)C)C(=O)N(CC(=O)O)C1=S.

